Sight Sciences, Inc. (SGHT) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Sight Sciences, Inc. is an ophthalmic medical device company operating in two segments: Interventional Glaucoma (OMNI Surgical System, SION Surgical Instrument) and Interventional Dry Eye (TearCare System). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) |
|---|---|---|
| Revenue | $23.4 million | $43.1 million |
| Gross Profit | $21.4 million | $38.4 million |
| Gross Margin | 91.4% | 89.0% |
| Net Loss | $(4.4) million | $(17.4) million |
| Operating Cash Flow | N/A | $(12.7) million used |
| Cash & Equivalents | $79.8 million | $79.8 million (as of June 30) |
| Total Debt (Principal) | $40.0 million | $40.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19.5% year-over-year (Q2) and 16.2% year-over-year (YTD).
- Interventional Glaucoma: Up 7.7% (Q2) driven by higher unit sales and average selling prices.
- Interventional Dry Eye: Surged 703.3% (Q2) and 454.1% (YTD) due to increased SmartLid volume and improved reimbursement access (CPT code 0563T).
- Margin Expansion: Gross margins improved to 91.4% (Q2) from 84.8% in the prior year, primarily due to $1.2 million in tariff refunds received in Q2 2026 and favorable product mix.
- Expense Reduction: Operating expenses decreased 10.6% (Q2) and 4.5% (YTD).
- R&D: Decreased 42.7% (Q2) due to reduced headcount and lower clinical study costs.
- SG&A: Decreased 4.7% (Q2) due to lower payroll and marketing costs, though YTD SG&A increased 2.5% due to a $5.4 million litigation success fee paid in Q1 2026 related to the Alcon patent verdict.
- Loss Narrowing: Net loss improved significantly, decreasing 62.8% in Q2 and 33.2% YTD compared to the prior year.
Outlook, Risks, and Contingencies
- Litigation (Alcon): The company secured a final judgment awarding $55.4 million in damages plus a 10% ongoing royalty on Hydrus revenue. Alcon has appealed the judgment. While one patent was confirmed valid by the USPTO, two others remain under reexamination, creating uncertainty regarding the final collectability of the award.
- Liquidity: Management believes current cash ($79.8 million) and existing credit facilities will fund operations for at least 12 months. The company maintains a $65.0 million credit facility with Hercules Capital, with $40.0 million currently drawn. The interest-only period was extended to February 1, 2027.
- Reimbursement: Continued focus on expanding reimbursement for TearCare products and protecting reimbursement for Glaucoma products remains a key strategic priority and risk factor.
- Debt Covenants: The company is in compliance with all covenants, including minimum cash and revenue requirements.
Investor Verification Checklist
- Alcon Litigation Status: Monitor the outcome of the remaining USPTO reexaminations and the appellate court proceedings, as these directly impact the potential $55.4 million recovery.
- Tariff Refund Sustainability: Verify if the $1.2 million tariff refund in Q2 is a one-time event or indicative of ongoing cost reductions.
- Dry Eye Reimbursement: Confirm the breadth of Medicare Administrative Contractor (MAC) fee schedules for CPT code 0563T to assess the sustainability of the 700%+ revenue growth in the Dry Eye segment.
- Debt Maturity: Review the repayment schedule for the $40 million Hercules term loan, noting the final payment fee of 5.95% due at maturity in 2028.
- Operating Cash Burn: Assess the trajectory of operating cash burn ($12.7 million YTD) against the $79.8 million cash balance to determine runway without additional financing.